Yoran Hummel

Do the math … 🦾🫀

1 𝐢𝐧 4 𝐝𝐢𝐚𝐛𝐞𝐭𝐢𝐜 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐡𝐚𝐝 𝐮𝐧𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞. 𝐌𝐨𝐬𝐭 𝐡𝐚𝐝 𝐧𝐨 𝐢𝐝𝐞𝐚. ‼️ Us2.ai is proud to be a partner in the landmark TARTAN-HF trial which showed that a widely available NT-proBNP blood test, followed by an echo scan, changed everything. ✅ 1 in 4 screened patients diagnosed compared to 1% in usual care. ✅ 55% reduction in hospitalisation or death. The evidence is here. Now health systems need to act.

😊 𝐌𝐞𝐞𝐭 𝐭𝐡𝐞 𝐭𝐞𝐚𝐦 𝐛𝐞𝐡𝐢𝐧𝐝 𝐔𝐬2.𝐚𝐢 👋 When you reach out to Us2.ai, these are the people you'll hear from. A small but mighty global sales team, passionate about bringing AI-powered echocardiography to clinicians and institutions around the world. In the video you'll meet: 🌏 Daniel Ishak — Asia-Pacific & Middle East 🌍 Nathan Simcox — Europe 🌎 Seth Koeppel — North & South America And while he couldn't make it on camera this time, rounding out the Americas team is the one and only Dave Ladd. Whether you're exploring AI echo for the first time or ready to bring Us2.ai into your institution, these are your people. Don't hesitate to reach out directly or drop a comment below and we'll get you connected.

4 weeks. That's all it took for Bordeaux University Hospital to go fully live with AI echo. 894 echos. 31 parameters. ICC up to 0.97. Peer-reviewed. GDPR compliant. No VPN. No disruption. Still hesitating about AI echo? Don't. 👇 📄: us2.ai/clinical-evide…

Stop making measurements manually! Sonographers face a real physical toll: neck pain, back pain, shoulder strain from scanning and manual measurements all day, when that time and energy could go toward what they were trained for: critical thinking, better imaging, and better patient outcomes. Us2.ai and Merge built this integration specifically to give that time back. Here's how it works: ✅ Sonographer scans the patient ✅ Us2.ai's FDA-cleared AI processes the echo in the background ✅ Results appear natively inside Merge Cardio, no extra clicks, no extra logins ✅ By the time the patient is seen out, the measurements are already done Think of it like CarPlay. The AI runs seamlessly in the background, without changing how clinicians work. No new systems to learn, no extra steps. Just switch it on and the results are already there. The result? Faster workflows. Healthier echo techs. Better patient care. 🎥 Watch the full interview with Cardiac Wire to hear how this works 👇

#ACC26 is a wrap and what a weekend it was! 🙌 We are so grateful to our partners @Merative, @viz_ai, and @FujifilmHealth for generously hosting us at their booths throughout the conference. Being able to show our solution live to clinicians on the ground is always a highlight and this year was no exception. A huge thank you to everyone who stopped by to learn more about what we are building. The conversations, the curiosity, and the enthusiasm from the echo community means everything to us. This is exactly why we do what we do. The interest in AI-powered echocardiography continues to grow and weekends like this remind us just how much momentum this space has. We are grateful to be part of it. Missed us this time? Do not fret! We will be on the road again soon. Follow us to be notified the next time we come to a city near you 🌍!

Us2.ai's echocardiography AI algorithm will be integrated into a new ATTR-CM care initiative led by @Alnylam in partnership with @viz_ai ! @Alnylam is partnering with @viz_ai, the leader in AI-powered disease detection and care coordination, to develop an AI-enabled ATTR-CM care pathway designed to help clinicians identify patients earlier and guide appropriate diagnostic evaluation and referral. The pathway combines Us2.ai's FDA-cleared echocardiography AI with EHR connectivity and integration into routine clinical practice to support earlier recognition of ATTR-CM and facilitate coordinated care across cardiology and heart failure teams. We are proud that our solution will play a role in getting more patients diagnosed earlier, when it matters most. Read the full press release: investors.alnylam.com/press-release?…

𝐓𝐡𝐢𝐬 𝐢𝐬 𝐰𝐡𝐚𝐭 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐥𝐨𝐨𝐤𝐬 𝐥𝐢𝐤𝐞 𝐰𝐢𝐭𝐡 𝐔𝐬𝟐.𝐚𝐢. What you are seeing: → Every view automatically identified and classified → Structures traced, measurements calculated → Disease detection in real time → A full structured report. Ready. Zero clicks. FDA cleared. CE marked. Running in clinical workflows across the world today. Curious how our solution could elevate your echo workflow? 👉 Book a demo at us2.ai

New paper in Circulation: Cardiovascular Imaging AI detection of cardiac amyloidosis from a single routine echo view 5,776 patients. UK, Taiwan, US, Japan. Sensitivity 88.5% | Specificity 87.2% | AUC 0.93 AI deep learning vide-based classifier outperforms the multiparametric score (0.93 vs 0.86, p<0.001). 🔗ahajournals.org/doi/10.1161/CI…

🔬 𝐖𝐞’𝐯𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐞𝐧 𝐠𝐫𝐨𝐮𝐧𝐝𝐞𝐝 𝐢𝐧 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞. 𝐍𝐨𝐰 𝐢𝐭’𝐬 𝐞𝐯𝐞𝐧 𝐞𝐚𝐬𝐢𝐞𝐫 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫𝐬. Our upgraded Clinical Evidence page brings together the validation studies behind our software alongside the growing body of research using Us2.ai in clinical and scientific projects. With new filters across a wide range of topics, there’s something here for everyone, whether you’re diving into the details or simply looking to satisfy your curiosity. A big thank you to every researcher and partner who has contributed. This page is for you too! 👉 us2.ai/clinical-evide…

💡 We know that bringing new technology into a health system takes more than clinical buy-in. That's why we've built out dedicated IT & Procurement resources on the new website, everything your technical and procurement teams need to evaluate, plan, and move forward with confidence. We've tried to make the process as smooth as possible. Take a look 👉 us2.ai/operations/it-…

𝐖𝐞’𝐯𝐞 𝐮𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐭𝐡𝐞 𝐔𝐬2.𝐚𝐢 𝐰𝐞𝐛𝐬𝐢𝐭𝐞!  🎉 This is more than a refreshed look. It’s a milestone that reflects how far we’ve come and where we’re headed next. New pages. New data. New resources. All built to showcase the real-world impact of AI-powered echo analysis. We’ll be rolling out highlights over the next week, but if you can’t wait, go take a look now 👀 🔗: us2.ai

🫀 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐢𝐬 𝐮𝐧𝐝𝐞𝐫𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐁𝐔𝐓, 𝐀𝐈 𝐜𝐚𝐧 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐚𝐭. We're proud to share our latest research published in 𝑪𝒊𝒓𝒄𝒖𝒍𝒂𝒕𝒊𝒐𝒏: 𝑪𝒂𝒓𝒅𝒊𝒐𝒗𝒂𝒔𝒄𝒖𝒍𝒂𝒓 𝑰𝒎𝒂𝒈𝒊𝒏𝒈: The development and external validation of Us2's deep learning model for automated detection of cardiac amyloidosis (CA) on echocardiography. Trained on 4,371 patients across the UK and Taiwan, and externally validated in the US and Japan across 5,776 patients in total, the results speak for themselves: ➡️ AUC 0.93 | 88.5% sensitivity | 87.2% specificity ➡️ Robust performance across age, sex, race, amyloid subtype and echo vendor ➡️ Consistently differentiates CA from other hypertrophic phenotypes including HCM, aortic stenosis, hypertension and CKD ➡️ Full report generated in 68 𝐬𝐞𝐜𝐨𝐧𝐝𝐬 Huge thanks to our collaborators at the National Amyloidosis Centre (UCL), Duke University Health System, National Cerebral and Cardiovascular Center (Japan), and MacKay Memorial Hospital (Taiwan). 📄 Read the full paper: us2.ai/clinical-evide… 📩 Contact us to learn more!

@WarrenVsCCP At a bare minimum take the time to search for the guy’s actual name when posting about him… Joep Wennemars

🚨🚨 Disgraceful CCP athletes!! This is footage of world champion Jupp Vinemars (Netherlands) colliding with Chinese athlete Lian Ziwen. Lian Ziwen claims it wasn't intentional, but it was indeed a serious obstruction foul. He knows the rules! An athlete can only participate in a world-class competition once every four years. Those trained by the CCP should not bring this kind of thing to the world stage. It's a disgrace to the Chinese people.

🗣️ 𝐀 𝐧𝐞𝐰 #JACC 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐡𝐚𝐬 𝐣𝐮𝐬𝐭 𝐝𝐫𝐨𝐩𝐩𝐞𝐝! Co-hosted by our co-founder @lamcardio this episode focuses on Cardiac Amyloidosis... 490 𝐝𝐚𝐲𝐬. That is the median delay to diagnosis reported in recent data. At the same time, mortality benefit in ATTR-CM trials emerges within 12–18 months. The field is moving from 𝑪𝒂𝒏 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒄𝒂𝒓𝒅𝒊𝒂𝒄 𝒂𝒎𝒚𝒍𝒐𝒊𝒅𝒐𝒔𝒊𝒔? to 𝑯𝒐𝒘 𝒅𝒐 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒆𝒂𝒓𝒍𝒊𝒆𝒓, 𝒂𝒏𝒅 𝒔𝒚𝒔𝒕𝒆𝒎𝒂𝒕𝒊𝒄𝒂𝒍𝒍𝒚? At Us2.ai, this is exactly the problem we are building for. 𝐎𝐮𝐫 𝐀𝐈 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐢𝐬 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐚𝐧𝐝 𝐨𝐧𝐥𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐡𝐚𝐭 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐁𝐎𝐓𝐇: ➡️ Automated, guideline-based chamber quantification and measurements ➡️ AI-driven pattern recognition By combining standardized measurements with disease-pattern analysis, AI can help surface high-risk patients earlier. When disease is progressive and increasingly treatable, systematic detection matters. 🎙️ Listen to the full podcast discussion!

Bye bye to ‘RV; the forgotten chamber’, hello to automation making us better! Big win for patients with #pulmonaryHT

🔎 𝐀𝐨𝐫𝐭𝐢𝐜 𝐒𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐔𝐬2.𝐚𝐢 Aortic stenosis is one of the most common and deadly valvular heart diseases, affecting approximately 12% of people over 75, with 1 in 4 severe symptomatic patients dying within 2 years if untreated. At Us2.ai, 𝐨𝐮𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐜𝐚𝐧 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐧𝐚𝐥𝐲𝐳𝐞 𝐞𝐜𝐡𝐨 𝐢𝐦𝐚𝐠𝐞𝐬 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐜𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐨𝐧 𝐚𝐨𝐫𝐭𝐢𝐜 𝐬𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐬𝐞𝐯𝐞𝐫𝐢𝐭𝐲, 𝐰𝐢𝐭𝐡 𝐳𝐞𝐫𝐨 𝐡𝐮𝐦𝐚𝐧 𝐢𝐧𝐩𝐮𝐭 𝐛𝐞𝐲𝐨𝐧𝐝 𝐢𝐦𝐚𝐠𝐞 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧. This capability is validated in a JASE publication demonstrating fully automated AI analysis across no, mild, moderate, and severe aortic stenosis cases:👉 lnkd.in/ga3FbaiT Watch this video where Dr. Hema Krishna discusses her aortic stenosis publication using the Us2.ai software. 💬Interested? Contact us now for a demo.

🆕 As we approach the new year, the Us2.ai team will be continuing to push the boundaries of AI-powered cardiac care. Next up on our disease detection roadmap: 𝐇𝐲𝐩𝐞𝐫𝐭𝐫𝐨𝐩𝐡𝐢𝐜 𝐂𝐚𝐫𝐝𝐢𝐨𝐦𝐲𝐨𝐩𝐚𝐭𝐡𝐲 (𝐇𝐂𝐌). We’re thrilled to share the first results of our HCM model, presented at ASE 2025 as a sneak peek of the work underway. 📖 : us2.ai/ai-automated-d… The journey is just beginning, and we can’t wait to show you what’s next. 𝐒𝐭𝐚𝐲 𝐭𝐮𝐧𝐞𝐝! 🔜

Still at #RSNA2025 today? Did you know that Us2.ai is now officially integrated with Merge by @Merative Cardio ❤️, helping institutions boost confidence in clinical outcomes and deliver higher-quality cardiac care. If your institution uses Merge and you’re exploring how AI can support your echocardiography workflow 💡📊, make sure to see the integration in action. 📍 Visit the Merge team at 𝐁𝐨𝐨𝐭𝐡 6100 in North Hall Don’t miss out! ✨

🎉 𝐖𝐞’𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐟𝐢𝐧𝐚𝐥𝐥𝐲 𝐬𝐡𝐚𝐫𝐞 𝐭𝐡𝐞 𝐧𝐞𝐰𝐬! Us2.ai is now partnering with Merge by Merative to transform cardiology diagnostics with AI-generated echocardiogram measurements. 💙 This partnership brings together Us2.ai’s cutting-edge, FDA-cleared algorithms with Merge Cardio’s advanced imaging systems, enabling fully AI-generated analysis and reporting of echocardiograms. We couldn’t be more excited to work alongside the Merge team to make AI-driven cardiac care accessible at scale. Read the full press release here: merative.com/newsroom/merge…